Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Generics Ltd.

Division of Glenmark Pharmaceuticals Ltd.
www.glenmark-generics.com

Latest From Glenmark Generics Ltd.

Legal News: Teva V. FDA, Pay-For-Delay, Citizen Petitions, User Fee Scheme

US court tosses Teva suit seeking generic Restasis exclusivity. FTC loses appeal challenging Shire's citizen petitions, settles Solvay pay-for-delay case. DoJ resolves FCA case alleging company made deal to avoid paying FDA user fees for two NDAs.

Legal Issues Intellectual Property

India Rupee Plunge Boon For Most Domestic Pharma Firms, But Gains May Be Delayed

The Indian rupee has played havoc with the country’s macroeconomic fundamentals and like in emerging markets such as Turkey, Brazil and Indonesia caused policymakers to carefully eye capital flows. But India’s unique position as a major drug manufacturer and exporter gives many of its companies the prospect of higher domestic earnings as sales are widely priced in dollars.

BioPharmaceutical India

Deals Shaping The Medical Industry, March 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011

Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.
BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Glenmark Pharmaceuticals Ltd.
  • Senior Management
  • Terrance J Coughlin, CEO
    Percy Birdy, VP, Fin.
  • Contact Info
  • Glenmark Generics Ltd.
    Phone: (91) 22 40 18 9999
    HDO-Corp. Bldg. Wing A
    Off W Express H
    Mumbai, 400099
    India
Advertisement
Advertisement
UsernamePublicRestriction

Register